Cytokines and cutaneous T-cell lymphomas

Experimental Dermatology

Volumn 7, Issue 6, 1998, Pages 314-320

  Asadullah, K ^a,b   Docke W D ^a   Volk, H D ^a   Sterry, W ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cutaneous lymphomas; Cytokines; Growth factors; Immunotherapy

Indexed keywords

ALPHA INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR;

CELL PROLIFERATION; HUMAN; IMMUNE RESPONSE; LYMPHOMA; MYCOSIS FUNGOIDES; NONHUMAN; PATHOGENESIS; REVIEW; SKIN BIOPSY; SKIN LYMPHOMA; T CELL LYMPHOMA; TUMOR CELL;

EID: 0031735592     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0625.1998.tb00330.x     Document Type: Review

References (64)

1. Hsu S M, Waldron J W Jr. Hsu P L, Hough A J Jr. Cytokines in malignant lymphomas: review and prospective evaluation. Hum Pathol 1993: 24: 1040-1057.
2. Rook A H, Vowels B R, Jaworsky C, Singh A, Lessin S R. The immunopathogenesis of cutaneous T-cell lymphoma. Abnormal cytokine production by Sézary T cells [editorial]. Arch Dermatol 1993: 129: 486-489.
3. Burg G, Haffner A, Boni R, Dommann S, Dummer R. New perspectives in experimental and clinical research for cutaneous T-cell lymphomas. Recent Results Cancer Res 1995: 139: 225-237.
4. Burg G, Kempf W, Haeffner A C et al. Cutaneous lymphomas. Curr Prob Dermatol 1997: 9: 137-204.
5. Romagnani S. Biology of human TH1 and TH2 cells. J Clin Immunol 1995: 15: 121-129.
6. Romagnani S. ThI and Th2 in human diseases. Clin Immunol Immunopathol 1996: 80: 225-235.
7. Mosmann T R, Cherwinski H, Bond M W, Giedlin M A, Coffman R L. Two types of murine helper T-cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986: 136: 2348-2357.
8. Mosmann T R. Li L, Sad S. Functions of CD8 T-cell subsets secreting different cytokine patterns. Semin Immunol 1997: 9: 87-92.
9. Kelso A. Th1 and Th2 subsets: paradigms lost? Immunol Today 1995: 16: 374-379.
10. Vollmer S, Menssen A, Trommler P, Schendel D, Prinz J C. T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol 1994: 24: 2377-2382.
11. Ohmen J D, Hanifin J M, Nickoloff B J et al. Overexpression of IL-10 in atopic dermatitis. Contrasting cytokine patterns with delayed-type hypersensitivity reactions. J Immunol 1995: 154: 1956-1963.
12. Tron V A, Rosenthal D, Sauder D N. Epidermal interleukin-1 is increased in cutaneous T-cell lymphoma. J Invest Dermatol 1988: 90: 378-381.
13. Lawlor F, Smith N P, Camp R D et al. Skin exudate levels of interleukin 6, interleukin 1 and other cytokines in mycosis fungoides. Br J Dermatol 1990: 123: 297-304.
14. Wismer J M, McKenzie R C, Sauder D N. Interleukin-8 immunoreactivity in epidermis of cutaneous T-cell lymphoma patients. Lymphokine Cytokine Res 1994: 13: 21-27.
15. Saed G M, Fivenson D P, Naidu Y, Nickoloff B J. Mycosis fungoides exhibits a Th1-type cell mediated cytokine profile whereas Sézary syndrome expresses a Th2-type profile. J Invest Dermatol 1994: 103: 29-33.
16. - lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma? Blood 1995: 86: 651-658.
17. Yamamoto T, Sasaki G, Sato T, Katayama I, Nishioka K. Cytokine profile of tumor cells in mycosis fungoides: successful treatment with intra-lesional interferon-gamma combined with chemotherapy. J Dermatol 1995: 22: 650-654.
18. Asadullah K, Döcke W D, Haeußler A, Sterry W, Volk H D. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol 1996: 107: 833-837.
19. Tensen C P, Vermeer M H, van der Stoop P M et al. Epidermal interferon-gamma inducible protein-10 (IP-10) and monokine induced by gamma-interferon (mig) but not IL-8 mRNA expression is associated with epidermotropism in cutaneous T-cell lymphomas. J Invest Dermatol 1998: 111: 222-326.
20. Vowels B R, Lessin S R, Cassin M et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 1994: 103: 669-673.
21. Lessin S R, Vowels B R, Rook A H. Th2 cytokine profile in cutaneous T-cell lymphoma. J Invest Dermatol 1995: 105: 855-856.
22. Saed G M, Fivenson D P, Nickoloff B J. Reply (letter). J Invest Dermatol 1995: 105: 856.
23. Chen Y, Kuchroo V K, Inobe J, Hafler A D, Weiner H L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994: 265: 1237-1240.
24. Fukaura H, Kent S C, Pietrusewicz M J, Khoury S J, Weiner H L, Hafler D A. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta 1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 1996: 98: 70-77.
25. Asadullah K, Döcke W D, Sabat R, Ebeling M, Volk H D, Sterry W. Interleukin-10 in Dermatology. Hautarzt 1998, in press.
26. Buhl L, Sogaard H. Immunohistochemical expression of IL-10 in mycosis fungoides. Exp Dermatol 1997: 6: 195-198.
27. Yagi H, Tokura Y, Furukawa F, Takigawa M. Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: successful treatment with recombinant interferon-gamma. J Invest Dermatol 1996: 107: 827-832.
28. Vermeer M H, Tensen C P, van der Stoop P M et al. Absence of the Th2 cytokines in primary cutaneous CD30-negative diffuse large cell lymphomas. J Invest Dermatol 1997: 109: 487 (abstract).
29. Dummer R, Heald P W, Nestle F O et al. Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood 1996: 88: 1383-1389.
30. Yagi H, Tokura Y, Furukawa F, Takigawa M. CD7-positive Sézary syndrome with a Th1 cytokine profile. J Am Acad Dermatol 1996. 34: 368-374.
31. Boehncke W H, Gerdes J, Wiese M, Kaltoft K, Sterry W. A majority of proliferating T cells in cutaneous malignant T-cell lymphomas may lack the high affinity IL-2 receptor (CD25). Arch Dermatol Res 1993: 285: 127-130.
32. Wasik M A, Seldin D C. Butmarc J R et al. Analysis of IL-2, IL-4 and their receptors in clonally-related cell lines derived from a patient with a progressive cutaneous T-cell lymphoproliferative disorder. Leuk Lymphoma 1996: 23: 125-136.
33. Dalloul A, Laroche L, Bagot M et al. Interleukin-7 is a growth factor for Sézary lymphoma cells. J Clin Invest 1992: 90: 1054-1060.
34. Foss F M, Koc Y, Stetler-Stevenson M A et al. Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: potential autocrine or paracrine effectors in the Sézary Syndrome. J Clin Oncol 1994: 12: 326-335.
35. von Freeden-Jeffry U, Vieira P, Lucian L A, McNeil T, Burdach S E, Murray R. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med 1995: 181: 1519-1526.
36. Peschon J J, Morrissey P J, Grabstein K H et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor deficient mice. J Exp Med 1994: 180: 1955-1960.
37. Rich B E, Campos-Torres J, Tepper R I, Moreadith R W, Leder P. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J Exp Med 1993: 177: 305-316.
38. Matsue H, Bergstresser P R, Takashima A. Keratinocyte-derived IL-7 serves as growth factor for dendritic epidermal T cells in mice. J Immunol 1993: 151: 6012-6019.
39. Bagot M, Charue D, Boulland M L et al. Interleukin-7 receptor expression in cutaneous T-cell lymphomas. Br J Dermatol 1996: 135: 572-575.
40. Asadullah K, Haeußler A, Friedrich M et al. IL-7 mRNA is not overexpressed in mycosis fungoides and pleomorphic T-cell lymphoma and is likely to be an autocrine growth factor in vivo. Arch Derm Res 1996: 289: 9-13.
41. Döbbeling U, Dummer R, Laine E, Potoczna N, Qin J Z, Burg G. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood 1998: 92: 252-258.
42. Bulfone-Paus S, Ungureanu D. Pohl T et al. Interleukin-15 protects from lethal apoptosis in vivo. Nat Med 1997: 3: 1124-1128.
43. Sterry W, Mycosis fungoides. Curr Top Pathol 1985: 74: 167-223.
44. Asadullah K, Haeußler A, Sterry W, Doc̈ke W D, Volk H D. Interferon-gamma and tumor necrosis factor mRNA expression in mycosis fungoides progression. Blood 1997: 88: 757-758.
45. Hoppe RT, Medeiros LJ, Warnke RA, Wood GS. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995: 32: 448-453.
46. Fiorentino D F, Zlotnik A, Vieira P et al. IL-10 acts on antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991: 146: 3444-3451.
47. Fiorentino D F, Zlotnik A, Mosmann T R, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991: 147: 3815-3822.
48. Matsuda M, Salazar F, Petersson M et al. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 1994: 180: 2371-2376.
49. Asadullah K, Sterry W, Stephanek K et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy; a new therapeutic approach. J Clin Invest 1998: 101: 783-794.
50. Asadullah K, Friedrich M, Haeubetaler A, Sterry W, Döcke W D, Volk H D. Granzyme A mRNA expression in mycosis fungoides progression. Blood 1997: 90: 3810-3811.
51. Oudejans J J, Jiwa N M, Kummer J A et al. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 1997: 89: 1276-1282.
52. Edelson R L. Cutaneous T-cell lymphoma: mycosis fungoides, Sézary syndrome, and other variants. J Am Acad Dermatol 1980: 2: 89-106.
53. Asadullah K, Friedrich F, Döcke W D, Jahn S, Volk H D, Sterry W. Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early primary cutaneous T-cell lymphoma. J Invest Dermatol 1997: 108: 743-747.
54. Dummer R, Kohl O, Gillessen J, Kagi M, Burg G. Peripheral blood mononuclear cells in patients with nonleukemic cutaneous T-cell lymphoma. Reduced proliferation and preferential secretion of a T helper-2-like cytokine pattern on stimulation. Arch Dermatol 1993: 129: 433-436.
55. Vowels B R, Cassin M, Vonderheid E C, Rook A H. Aberrant cytokine production by Sézary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992: 99: 90-94.
56. Rook A H, Kubin M, Cassin M et al. IL-12 reverses cytokine and immune abnormalities in Sézary syndrome. J Immunol 1995: 154: 1491-1498.
57. Kantor A F, Curtis R E, Vonderheid E C, van Scott E J, Fraumeni J F. Risk of second malignancy after cutaneous T-cell lymphoma. Cancer 1989: 63: 1612-1615.
58. Harwix S, Zachmann K, Flörl S, Jung T, Reich K, Neumann C. Evidence against a Th2 cytokine profile in early stage cutaneous T-cell-lymphoma. J Invest Dermatol 1998: 110: 642 (abstract).
59. Gellrich S, Golembowski S, Audring H, Jahn S, Sterry W. Molecular analysis of the immunoglobulin VH gene rearrangement in a primary cutaneous immunoblastic B-cell lymphoma by micromanipulation and single-cell PCR. J Invest Dermatol 1997: 109: 541-545.
60. Friedrich M, Henze M, Döcke W D et al. Characterization of cutaneous lymphocytes - possibilities and limits. J Invest Dermatol 1998: 110: 586 (abstract).
61. Rook A H, Gottlieb S L, Wolfe J T et al. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis. Clin Exp Immunol 1997: 107: 16-20.
62. Rook A H, Yoo E K, Grossman D J, Kao D M F, Fox F E, Niu Z. Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma. Curr Opin Oncol 1998: 10: 170-174.
63. Klein B, Wijdenes J, Zhang X G et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991: 78: 1198-1204.
64. van Zaanen H C, Koopmans R P, Aarden L A et al. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest 1996: 98: 1441-1448.